Investigating Endometrial Cancer Staging Systems
Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO)
Recruiting
Observational Study
Clinicopathological
Endometrial Carcinoma
Federation of Gynecology and Obestetrics
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 110 (estimated)
- Sponsor
- Assiut University · Other
Who this trial is looking for
This trial is looking for patients with endometrial cancer who had surgery between 2018 and 2022. Participants will help researchers understand how new staging guidelines affect treatment and survival.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with endometrial cancer
- I had surgery for my cancer between January 1, 2018, and December 31, 2022
- I have medical records available from my diagnosis
- I have at least 2 years of follow-up after my surgery
- I received additional treatment after my surgery
- I have histopathological slides and blocks available
You may not be able to join if
- I received chemotherapy before my surgery
- I have had endometrial cancer come back
- I have multiple types of cancer
- I do not have my histopathological slides and blocks
- I do not have my medical records
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Assess the percentage change in stage and risk stratification for patients with endometrial cancer when transitioning from the FIGO 2009 endometrial staging system to the updated FIGO 2023 endometrial staging system.
Investigate the prognostic impact of the FIGO 2023 endometrial staging system on patient survival.
Evaluate how the shift in stage classification between the FIGO 2009 and FIGO 2023…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
\- Patients diagnosed with endometrial cancer (EC) who underwent surgical staging (total hysterectomy and bilateral salpingo-oophorectomy) between January 1, 2018, and December 31, 2022 with available medical records since diagnosis and at least follow up 2 years and received ad…
Contacts